SCHEMBL269018

SCHEMBL269018

NCC(=O)NC1CCCCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 6/20 0.61
HPGD P15428 3/20 0.61
KMT2A Q03164 1/20 0.61
SMN1; SMN2 Q16637 3/20 0.59
ALDH1A1 P00352 2/20 0.59
NPSR1 Q6W5P4 1/20 0.57
NPC1 O15118 3/20 0.56
RAB9A P51151 3/20 0.56
CYP3A4 P08684 2/20 0.56
EPHX2 P34913 2/20 0.56
MAPT P10636 1/20 0.56
KDM4E B2RXH2 1/20 0.56
LMNA P02545 1/20 0.55
CYP2C19 P33261 1/20 0.52
HDAC3 O15379 1/20 0.50
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
HDAC10 Q969S8 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
HDAC8 Q9BY41 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23475863 1.00 EPHX1 (0.61) EPHX1HPGDKMT2ASMN1; SMN2ALDH1A1
SCHEMBL23475876 1.00 EPHX1 (0.61) EPHX1HPGDKMT2ASMN1; SMN2ALDH1A1
SCHEMBL22546754 1.00 EPHX1 (0.61) EPHX1HPGDKMT2ASMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL7307604 0.98 EPHX1 (0.59) EPHX1HPGDKMT2ASMN1; SMN2ALDH1A1
SCHEMBL991938 0.98 SMN1; SMN2 (0.61) EPHX1HPGDKMT2ASMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL3512220 0.95 SMN1; SMN2 (0.59) EPHX1HPGDKMT2ASMN1; SMN2ALDH1A1
SCHEMBL31723928 0.93
SCHEMBL3135300 0.88
SCHEMBL16853215 0.88 SMN1; SMN2 (0.48) EPHX1HPGDKMT2ASMN1; SMN2ALDH1A1
Hydrochloric Acid SCHEMBL1996186 0.86

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2385948-B1 FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES TORRENT PHARMACEUTICALS LTD (IN) 2017-10-04 EP claimed
WO-2011008915-A1 PYRROLOPYRIDINE INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2011-01-20 WO claimed
CN-119875056-A Polyurea material and supercritical foaming composite midsole 福建鑫瑞新材料科技有限公司 2025-04-25 CN disclosed
US-11339128-B2 Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers FIRMENICH INCORPORATED (US) 2022-05-24 US disclosed
CN-113430595-A Method for plating copper on surface of brass casting 惠州市安泰普表面处理科技有限公司 2021-09-24 CN disclosed
EP-3096751-B1 12-EPI-PLEUROMUTILINS Nabriva Therapeutics GmbH (AT) 2021-01-06 EP disclosed
CN-104962221-B A kind of glass curtain wall structure sealant and preparation method thereof 香山红叶建设有限公司 2018-07-13 CN disclosed
WO-2017005073-A1 STRUCTURAL SEALANT FOR GLASS CURTAIN WALL AND PREPARATION METHOD THEREFOR 梁怡芃 2017-01-12 WO disclosed
CN-104927727-B Structural sealant for glass curtain walls and preparation method for structural sealant 香山红叶建设有限公司 2017-01-11 CN disclosed
CN-104962221-A Structural sealant for glass curtain wall and preparation method for structural sealant Shandong xiangshan decoration engineering co ltd 2015-10-07 CN disclosed
CN-104927727-A Structural sealant for glass curtain walls and preparation method for structural sealant WANG SHUYI 2015-09-23 CN disclosed
US-6518458-B1 ((aminoiminomethyl)amino)alkane-carboxamide type in the treatment of pathologies associated with insulin resistance syndrome. MERCK PATENT GMBH (DE) 2003-02-11 US disclosed
EP-1140803-A1 ((AMINOIMINOMETHYL) AMINO) ALKANECARBOXAMIDES AND THEIR APPLICATIONS IN THERAPY MERCK PATENT GmbH (DE) 2001-10-10 EP disclosed
WO-2000042001-A1 ((AMINOIMINOMETHYL) AMINO) ALKANECARBOXAMIDES AND THEIR APPLICATIONS IN THERAPY MERCK PATENT GMBH (DE) 2000-07-20 WO disclosed
US-5459147-A Angeotensin-antagonistic effects; hypotensive, antiischemic, and antidiabetic agents, treating glaucoma DR. KARL THOMAE GMBH (DE) 1995-10-17 US disclosed
US-4761416-A ENZYME INHIBITORS, INOTROPIC AGENTS SYNTEX (U.S.A.) INC. (US) 1988-08-02 US disclosed
US-4739056-A ENZYME INHIBITORS SYNTEX (U.S.A.) INC. (US) 1988-04-19 US disclosed
EP-0254327-A2 N-N-disubstituted-omega-(2-amino-3-(carbonylmethyl)-3,4-dihydroquinazolinyl) oxyalkylamides and related compounds SYNTEX (U.S.A.) INC. (US) 1988-01-27 EP disclosed
US-4690925-A ANTITHROMBOTIC ACTIVITY, CARDIOTONIC AGENTS SYNTEX (U.S.A.) INC. (US) 1987-09-01 US disclosed
EP-0153152-A2 (2-Oxo-1,2,3,5-tetrahydroimidazo-/2,1-b/quinnazolinyl)-oxyalkylamides, their preparation, compositions containing them and their use in making medicaments SYNTEX (U.S.A.) INC. (US) 1985-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11339128-B2 Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers TAS2R5, TAS2R4, TAS2R30 EPHX1 3634/4885HPGD 2117/4885KMT2A 1024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.